Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage

[1] Macdonald RL(2010)Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials Neurocrit Care 13 416-424

[2] Higashida RT(2009)Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage Neurocrit Care 10 141-147

[3] Keller E(2009)Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis Stroke 40 3403-3406

[4] Mayer SA(2011)Protection effect of endothelin receptor antagonist on blood vessel in patients with subarachnoid hemorrhage China Pharm 22 525-529

[5] Molyneux A(2008)Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial Stroke 39 1759-1765

[6] Raabe A(2009)Which H is the most important in triple-H therapy for cerebral vasospasm Curr Opin Crit Care 15 83-86

[7] Vajkoczy P(2009)Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor Hypertension 54 676-683

[8] Wanke I(2008)Nitric oxide does not down regulate Rho-kinase (ROCK-2) expression in rat coronary endothelial cells J Cardiovasc Pharmacol 51 140-147

[9] Frey A(2009)Involvement of Rho-kinase in tumor necrosis factor-alpha-induced interleukin-6 release from C6 glioma cells Neurochem Int 55 438-445

[10] Marr A(2010)Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage Brain Res Bull 81 191-195

[1] Macdonald RL(2010)Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials Neurocrit Care 13 416-424

[2] Higashida RT(2009)Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage Neurocrit Care 10 141-147

[3] Keller E(2009)Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis Stroke 40 3403-3406

[4] Mayer SA(2011)Protection effect of endothelin receptor antagonist on blood vessel in patients with subarachnoid hemorrhage China Pharm 22 525-529

[5] Molyneux A(2008)Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial Stroke 39 1759-1765

[6] Raabe A(2009)Which H is the most important in triple-H therapy for cerebral vasospasm Curr Opin Crit Care 15 83-86

[7] Vajkoczy P(2009)Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor Hypertension 54 676-683

[8] Wanke I(2008)Nitric oxide does not down regulate Rho-kinase (ROCK-2) expression in rat coronary endothelial cells J Cardiovasc Pharmacol 51 140-147

[9] Frey A(2009)Involvement of Rho-kinase in tumor necrosis factor-alpha-induced interleukin-6 release from C6 glioma cells Neurochem Int 55 438-445

[10] Marr A(2010)Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage Brain Res Bull 81 191-195